Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Humana, Feeding America® Partner to Support Mobile Food Pantries
Humana, Feeding America® Partner to Support Mobile Food Pantries


Leading health and wellness company Humana Inc. (NYSE: HUM) is helping to address food insecurity with a $625,000 grant to Feeding America, supporting mobile food pantries in nine states.


This

Inogen Achieves Regulatory Milestones to Support Current and Future Products
Inogen Achieves Regulatory Milestones to Support Current and Future Products


Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it has achieved regulatory milestones in the

Inogen Announces Preliminary Fourth Quarter and Full Year 2022 Revenue Within Company Expectations
Inogen Announces Preliminary Fourth Quarter and Full Year 2022 Revenue Within Company Expectations


Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced unaudited preliminary revenue results for the

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
EQS-News: Sernova and Evotec on Track to Initiate Clinical Testing of the First iPSC-Derived Islets in Cell Pouch as a Potential Functional Cure for Type 1 Diabetes
EQS-News: Sernova and Evotec on Track to Initiate Clinical Testing of the First iPSC-Derived Islets in Cell Pouch as a Potential Functional Cure for Type 1 Diabetes
EQS-News: Sernova and Evotec on Track to Initiate Clinical Testing of the First iPSC-Derived Islets in Cell Pouch as a Potential Functional Cure for Type 1 Diabetes
Agilent Authorizes $2 Billion Share Repurchase Program
Agilent Authorizes $2 Billion Share Repurchase Program


Agilent Technologies Inc. (NYSE: A) today announced that its board of directors has approved a new share repurchase program. The 2023 program authorizes the purchase of up to $2 billion of the

Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2022 and Initial 2023 Outlook
Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2022 and Initial 2023 Outlook


DexCom, Inc. (Nasdaq: DXCM), the leader in real-time continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31

Dexcom Appoints Teri Lawver as Chief Commercial Officer
Dexcom Appoints Teri Lawver as Chief Commercial Officer


DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the appointment of Teri Lawver to the newly created role of chief

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
QuidelOrtho Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2022: https://s24.q4cdn.com/594651504/files/design/QO_Logo_FINAL.png
QuidelOrtho Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2022


QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and

Agilent and Akoya Biosciences Announce Partnership to Drive Multiplex Tissue Assay Development for Biopharma Applications:
Agilent and Akoya Biosciences Announce Partnership to Drive Multiplex Tissue Assay Development for Biopharma Applications


Agilent Technologies, Inc. (NYSE: A) today announced a partnership with Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, to develop multiplex-immunohistochemistry diagnostic

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Waters Corporation Recognized for its Award-winning Products, Outstanding Leadership, and ESG Progress
Waters Corporation Recognized for its Award-winning Products, Outstanding Leadership, and ESG Progress


Waters Corporation (NYSE:WAT) announced awards and recognitions from multiple independent industry organizations throughout 2022, highlighting strength and momentum of the company’s product

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Half-year liquidity contract statement for Sartorius Stedim Biotech
Half-year liquidity contract statement for Sartorius Stedim Biotech
Half-year liquidity contract statement for Sartorius Stedim Biotech
Sonova launches Conversation Clear Plus earbuds, expanding into the new category of early entry hearing solutions
Sonova launches Conversation Clear Plus earbuds, expanding into the new category of early entry hearing solutions
Sonova launches Conversation Clear Plus earbuds, expanding into the new category of early entry hearing solutions
Simulations Plus Reports First Quarter Fiscal 2023 Financial Results
Simulations Plus Reports First Quarter Fiscal 2023 Financial Results


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its first

Acadia Healthcare to Present at the 41st Annual J.P. Morgan Healthcare Conference
Acadia Healthcare to Present at the 41st Annual J.P. Morgan Healthcare Conference


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will present at the 41st Annual J.P. Morgan Healthcare Conference, January 9-12, 2023, at The Westin St. Francis, San

Agilent Announces Acquisition of Avida Biomed, Developer of High-Performance NGS Target Enrichment Workflows for Cancer Research:
Agilent Announces Acquisition of Avida Biomed, Developer of High-Performance NGS Target Enrichment Workflows for Cancer Research


Agilent Technologies Inc. (NYSE: A) today announced the acquisition of Avida Biomed, an early-stage life sciences company that develops high-performance target enrichment workflows with unique

Premier, Inc. to Report Fiscal 2023 Second-Quarter Results and Host Conference Call on February 7, 2023
Premier, Inc. to Report Fiscal 2023 Second-Quarter Results and Host Conference Call on February 7, 2023


Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2023 second quarter on Tuesday, February 7, at approximately 6:30 a.m. EST. The company will also

Dexcom to Present at 41st Annual J.P. Morgan Healthcare Conference
Dexcom to Present at 41st Annual J.P. Morgan Healthcare Conference


DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 41st annual J.P. Morgan Healthcare

Premier Inc. to Participate in 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023
Premier Inc. to Participate in 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023


Premier Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that members of its management team will participate in the 41st Annual J.P. Morgan

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc